Sector News

WSJ: Salix inventory issues helped scuttle Allergan buyout

November 10, 2014
Life sciences
At one time, Allergan felt confident it could lock up an acquisition of Salix Pharmaceuticals to thwart Valeant’s hostile bid. So confident, in fact, that it reportedly snubbed potential white knight Actavis when it came calling. But those talks have long since stalled, and now, Salix is investigating an inventory blip that The Wall Street Journal’s sources say was a dealbreaker for Allergan.
 
On Thursday, Salix announced that CFO Adam Derbyshire was headed for the door, and CEO Carolyn Logan said on a call with investors that its board’s audit committee had launched a review of “issues related to management’s prior characterization of wholesaler inventory levels.”
 
The reason? Supply levels for top drug Xifaxan and others are months higher than the company had previously communicated, meaning demand for Salix’s products may not have been as high as earlier revenue numbers suggested. As wholesalers sell off their supplies–9 months’ worth, in the case of Xifaxan, instead of the 10 to 12 weeks’ worth the company had signaled–Salix may not be able to keep sales as high as they’ve been. On that front, the North Carolina drugmaker said it now expects 2014 net income of $400 million, down from its earlier forecasts of $475 million.
 
Concerns over those industry levels stopped the Allergan takeover in its tracks, according to the WSJ. Though the two companies were close to an agreement in September, Allergan took a step back after determining Salix had more product supplies than expected. As Leerink Partners analyst Jason Gerberry wrote in a note to investors on Thursday, the situation also raises questions about Salix’s now-dead deal for the Irish unit of Italy’s Cosmo Pharmaceuticals, a breakdown the drugmaker blamed on new, stricter U.S. rules on tax inversions.
 
For Allergan’s part, without Salix, the company may be gobbled up by an acquirer in the near future–though the Botox maker is seeming more amenable to that idea lately, provided the acquirer isn’t longtime predator Valeant. In what industry watchers consider a thinly veiled reference to Actavis, Allergan said this week it was in talks with an anonymous third party.
 
The “board has determined that premature disclosure with respect to the possible terms of any transaction might jeopardize continuation of any discussions or negotiations,” it said in an SEC filing.
 
By Carly Helfand
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend